Lowest-Rated StocksLowest-RatedNASDAQ:MRNA Moderna (MRNA) Stock Price, News & Analysis $48.12 +2.40 (+5.25%) Closing price 04:00 PM EasternExtended Trading$48.14 +0.03 (+0.05%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Moderna Stock (NASDAQ:MRNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Moderna alerts:Sign Up Key Stats Today's Range$45.95▼$48.7750-Day Range$45.72▼$55.9752-Week Range$22.28▼$59.55Volume4.77 million shsAverage Volume9.68 million shsMarket Capitalization$19.09 billionP/E RatioN/ADividend YieldN/APrice Target$35.73Consensus RatingReduce Company Overview Moderna, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses. Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions. Beyond COVID-19, the company is developing vaccines targeting influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV) and Zika virus, as well as combination vaccines designed to protect against multiple respiratory pathogens. In addition to vaccines, Moderna is exploring mRNA therapeutics for oncology, rare diseases and cardiovascular conditions, leveraging partnerships with academic institutions and government agencies to accelerate development. The company was co-founded by a team of scientists and backed by Flagship Pioneering. Stéphane Bancel joined as chief executive officer in 2011 and has overseen Moderna’s rapid growth from a research-stage enterprise to a globally recognized biopharmaceutical company. Under his leadership, Moderna established large-scale manufacturing capabilities and forged collaborations with public health bodies such as the Biomedical Advanced Research and Development Authority (BARDA) in the United States and the Coalition for Epidemic Preparedness Innovations (CEPI). Moderna’s operations extend worldwide, with regional offices across North America, Europe and Asia-Pacific, and manufacturing facilities in the United States and Europe. The company continues to expand its global footprint through strategic alliances, technology transfer agreements and participation in international vaccine distribution initiatives. As it advances its mRNA platform, Moderna aims to build a diversified portfolio of products to address both emerging and longstanding public health challenges.AI Generated. May Contain Errors. Read More Moderna Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreMRNA MarketRank™: Moderna scored higher than 27% of companies evaluated by MarketBeat, and ranked 749th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.9 / 5Analyst RatingReduce Consensus RatingModerna has received a consensus rating of Reduce. The company's average rating score is 1.84, and is based on no strong buy ratings, 2 buy ratings, 12 hold ratings, and 5 sell ratings.Downside RiskModerna has a consensus price target of $35.73, representing about 25.7% downside from its current price of $48.12.Amount of Analyst CoverageModerna has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Moderna's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Moderna are expected to grow in the coming year, from ($6.79) to ($4.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Moderna is -5.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Moderna is -5.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioModerna has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Moderna's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.47% of the float of Moderna has been sold short.Short Interest Ratio / Days to CoverModerna has a short interest ratio ("days to cover") of 10.15, which indicates bearish sentiment.Change versus previous monthShort interest in Moderna has recently decreased by 1.90%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldModerna does not currently pay a dividend.Dividend GrowthModerna does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.20 News SentimentModerna has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Moderna this week, compared to 10 articles on an average week.Search Interest52 people have searched for MRNA on MarketBeat in the last 30 days. This is an increase of 53% compared to the previous 30 days.MarketBeat Follows16 people have added Moderna to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Moderna insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,661,254.00 in company stock.Percentage Held by Insiders10.80% of the stock of Moderna is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.33% of the stock of Moderna is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Moderna's insider trading history. Receive MRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRNA Stock News HeadlinesHHS cancels funding for Moderna vaccines to fight pandemic fluMay 19 at 2:48 PM | msn.comModerna, Inc. (MRNA) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 19 at 1:03 PM | seekingalpha.comTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that night, the dollar has lost over 85% of its purchasing power - and retirement savers have absorbed the cost. U.S. Code Title 31, Section 5117 gives the Treasury authority to reprice America's gold reserves from $42 per ounce to today's market value - a gap of 107x. More than 60 million Americans can move into physical gold inside a retirement account, tax-free and penalty-free.May 20 at 1:00 AM | Americas Gold Company (Ad)Moderna (NASDAQ:MRNA) President Stephen Hoge Sells 53,336 SharesMay 19 at 4:01 AM | insidertrades.comAssessing Moderna (MRNA) Valuation After Flu Vaccine Trial Success And Hantavirus Research AttentionMay 16, 2026 | finance.yahoo.comHantavirus: Is there a risk of another pandemic?May 16, 2026 | finance.yahoo.comModerna Recognized by TIME as One of the World’s Most Impactful CompaniesMay 13, 2026 | usatoday.comModerna (NASDAQ:MRNA) Director Sells $264,951.66 in StockMay 5, 2026 | insidertrades.comSee More Headlines MRNA Stock Analysis - Frequently Asked Questions How have MRNA shares performed this year? Moderna's stock was trading at $29.49 at the start of the year. Since then, MRNA stock has increased by 63.2% and is now trading at $48.12. How were Moderna's earnings last quarter? Moderna, Inc. (NASDAQ:MRNA) released its quarterly earnings results on Friday, May, 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.02) by $0.38. Moderna's revenue for the quarter was up 260.2% on a year-over-year basis. Read the conference call transcript. When did Moderna IPO? Moderna (MRNA) raised $604 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 26,275,993 shares at a price of $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers. Who are Moderna's major shareholders? Top institutional shareholders of Moderna include First Trust Advisors LP (0.60%), Dimensional Fund Advisors LP (0.54%), Bank of New York Mellon Corp (0.43%) and Bank of America Corp DE (0.25%). Insiders that own company stock include Stephane Bancel, Stephen Hoge, Shannon Thyme Klinger, Abbas Hussain, James M Mock, Noubar Afeyan and Arpa Garay. View institutional ownership trends. How do I buy shares of Moderna? Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Moderna own? Based on aggregate information from My MarketBeat watchlists, some other companies that Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings5/01/2026Today5/20/2026Bernstein 42nd Annual Strategic Decisions Conference5/28/2026Status update6/25/2026Next Earnings (Estimated)7/31/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 MRNA's financial health is in the Green zone, according to TradeSmith. MRNA has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRNA CIK1682852 Webwww.modernatx.com Phone(617) 714-6500FaxN/AEmployees4,700Year Founded2010Price Target and Rating Average Price Target for Moderna$35.73 High Price Target$69.00 Low Price Target$17.00 Potential Upside/Downside-25.7%Consensus RatingReduce Rating Score (0-4)1.84 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)($8.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.82 billion Net Margins-143.55% Pretax Margin-141.03% Return on Equity-26.64% Return on Assets-19.32% Debt Debt-to-Equity Ratio0.08 Current Ratio2.41 Quick Ratio2.35 Sales & Book Value Annual Sales$2.20 billion Price / Sales8.66 Cash FlowN/A Price / Cash FlowN/A Book Value$18.67 per share Price / Book2.58Miscellaneous Outstanding Shares396,786,000Free Float353,933,000Market Cap$19.09 billion OptionableOptionable Beta1.05 Social Links The 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:MRNA) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredFed story no one is tellingJ.P. Morgan's Private Bank quietly advised 333 billionaire families to move 60% of their portfolios into alter...TradeSmith | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moderna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moderna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
